Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 45

Sort by

Sort Order Select

Journal Articles

Microrna-143 Blocks ERK5 Signaling During Granulocytic Differentiation of Hematopoietic Stem Cells and Is Downregulated in AML

Jens-Uwe Hartmann, Daniela Braeuer-Hartmann, Cindy Schödel, Dennis Gerloff, Christiane Katzerke, Carsten Müller-Tidow, Daniel G. Tenen, MD, Dietger Niederwieser, Gerhard Behre, MD

Blood (2012) 120 (21): 3516.

https://doi.org/10.1182/blood.V120.21.3516.3516

Published: 2012

Journal Articles

Sorafenib Versus Placebo in Addition to Standard Therapy in Adult Patients ≥60 Years with Newly Diagnosed Acute Myeloid Leukemia: Results From the Randomized-Controlled Soraml Trial

Blood (2012) 120 (21): 144.

https://doi.org/10.1182/blood.V120.21.144.144

Published: 2012

Journal Articles

Allogeneic Stem Cell Transplantation Versus Conventional Postremission Therapy for Acute Myeloid Leukemia in First Complete Remission: A Matched Pairs Analysis

Blood (2012) 120 (21): 1974.

https://doi.org/10.1182/blood.V120.21.1974.1974

Published: 2012

Journal Articles

DNA Methyltransferase 3B (DNMT3B) Protein Expression Predicts Survival in Patients with Acute Myeloid Leukemia (AML)

Tim Sauer, MD, Christina Drusio, Irawan Wisudanto, Kim Friedel, Petra Tschanter, MD, Nils H. Thoennissen, MD, Cristina Sauerland, MSc, Gabriele Köhler, MD, Thomas Büchner, MD, Wolfgang E. Berdel, MD, Utz Krug, Carsten Müller-Tidow

Blood (2012) 120 (21): 1395.

https://doi.org/10.1182/blood.V120.21.1395.1395

Published: 2012

Journal Articles

A Specific DNA Methylation Pattern Is Associated with Delayed Leukemogenesis and Altered Response to Chemotherapeutic Treatment in an Inducible DNMT3b Expressing Mouse Model

Isabell Schulze, Petra Tschanter, MD, Christian Rohde, PhD, Nicole Baeumer, Heinz Linhart, Katja Hebestreit, Wolfgang E. Berdel, MD, Martin Dugas, MD, Carsten Müller-Tidow

Blood (2012) 120 (21): 398.

https://doi.org/10.1182/blood.V120.21.398.398

Published: 2012

Journal Articles

Phase I/II Study of Volasertib (BI 6727), an Intravenous Polo-Like Kinase (Plk) Inhibitor, in Patients with Acute Myeloid Leukemia (AML): Results From the Randomized Phase II Part for Volasertib in Combination with Low-Dose Cytarabine (LDAC) Versus LDAC Monotherapy in Patients with Previously Untreated AML Ineligible for Intensive Treatment

Johan Maertens, MD, PhD, Michael Lübbert, MD, Walter Fiedler, MD, Loic Fouillard, Alf Haaland, MD, Joseph M. Brandwein, MD, Stéphane Lepretre, MD, Oumédaly Reman, MD, Pascal Turlure, MD, Gesine Bug, Carsten Müller-Tidow, Alwin Krämer, MD, Florian Voss, PhD, Tillmann Taube, MD, Holger Fritsch, PhD, Hartmut Döhner, MD

Blood (2012) 120 (21): 411.

https://doi.org/10.1182/blood.V120.21.411.411

Published: 2012

Journal Articles

Phase I/II Study of Volasertib (BI 6727), An Intravenous Polo-Like Kinase (Plk) Inhibitor, in Patients with Acute Myeloid Leukemia (AML): Updated Results of the Dose Finding Phase I Part for Volasertib in Combination with Low-Dose Cytarabine (LD-Ara-C) and As Monotherapy in Relapsed/Refractory AML

Gesine Bug, MD, Carsten Müller-Tidow, MD, Richard F Schlenk, MD, Alwin Krämer, MD, Michael Lübbert, MD, PhD, Utz Krug, MD, Florian Voss, PhD, Tillmann Taube, MD, Holger Fritsch, PhD, Pilar Garin-Chesa, MD, PhD, Oliver G Ottmann, MD, Hartmut Döhner, MD

Blood (2011) 118 (21): 1549.

https://doi.org/10.1182/blood.V118.21.1549.1549

Published: 2011

Journal Articles

Differential Activity of Pazopanib and Imatinib Against PDGFRA-Related MPN and AML

Steffen Koschmieder, MD, Mirle Schemionek, PhD, Christian Elling, PhD, Utz Krug, MD, Torsten Kessler, MD, Wolfgang E. Berdel, Carsten Müller-Tidow, MD

Blood (2011) 118 (21): 5153.

https://doi.org/10.1182/blood.V118.21.5153.5153

Published: 2011

Journal Articles

Identification of the PML-RARα Associated DNA Methylome Using Reduced Representation Bisulfite Sequencing in Primary Patient Samples

Christian Rohde, PhD, Till Schoofs, Katja Hebestreit, Hans-Ulrich Klein, PhD, Anika Witten, PhD, Monika Stoll, PhD, Eva Lengfelder, MD, Wolf-Karsten Hofmann, MD, Peter Schlenke, PhD, Stefanie Göllner, PhD, Thomas Büchner, MD, Maria Cristina Sauerland, Steffen Koschmieder, MD, Wolfgang E. Berdel, Martin Dugas, MD, Carsten Müller-Tidow, MD

Blood (2011) 118 (21): 2436.

https://doi.org/10.1182/blood.V118.21.2436.2436

Published: 2011

Journal Articles

No Benefit of Combining Additional Compounds with Standard High Dose Cytarabine Consolidation: Results of the Prospective Randomized AML2003 Study

Blood (2011) 118 (21): 255.

https://doi.org/10.1182/blood.V118.21.255.255

Published: 2011

Journal Articles

Loss of EZH2 and Aberrant DNA Methylation Account for PKC412 Drug Resistance in the FLT3-ITD Positive Acute Myeloid Leukemia (AML) Cell Line MV4-11,

Stefanie Göllner, PhD, Tino Schenk, PhD, Christian Rohde, PhD, Arthur Zelent, PhD, Friedrich Stölzel, MD, Christian Thiede, MD, Wolfgang E. Berdel, Carsten Müller-Tidow, MD

Blood (2011) 118 (21): 3468.

https://doi.org/10.1182/blood.V118.21.3468.3468

Published: 2011

Journal Articles

A Distinct DNA Methylation Pattern Characterizes Childhood Acute Lymphoblastic Leukemia and Separates Patients Into Prognostic Groups,

Stefanie Göllner, PhD, Anika Witten, PhD, Monika Stoll, PhD, Wolfgang E. Berdel, Martin Schrappe, MD, Gunnar Cario, MD, Martin Stanulla, MD, MSc, Carsten Müller-Tidow, MD

Blood (2011) 118 (21): 3568.

https://doi.org/10.1182/blood.V118.21.3568.3568

Published: 2011

Journal Articles

DNMT3B Expression Delays Leukemogenesis,

Petra Tschanter, MD, Isabell Schulze, Nicole Bäumer, Beate Surmann, Konstantin Agelopoulos, Utz Krug, MD, Wolfgang E. Berdel, MD, Heinz Linhart, Carsten Müller-Tidow, MD

Blood (2011) 118 (21): 3446.

https://doi.org/10.1182/blood.V118.21.3446.3446

Published: 2011

Journal Articles

Histone H3 Methylation Mediates All- Trans -Retinoic Acid Responsiveness in Acute Myeloid Leukemia

Tino Schenk, PhD, Stefanie Göllner, PhD, Weihsu Claire Chen, PhD, Louise Howell, BSc, Liqing Jin, MD, Katja Hebestreit, Hans-Ulrich Klein, PhD, Alan K Burnett, MD, Ken I. Mills, PhD, FRCPath, Laurence Marton, MD, Robert Casero, Jr., PhD, Patrick Woster, PhD, Martin Dugas, MD, Jean C.Y. Wang, MD, PhD, John E. Dick, PhD, Carsten Müller-Tidow, MD, Kevin Petrie, PhD, Arthur Zelent, PhD

Blood (2011) 118 (21): 224.

https://doi.org/10.1182/blood.V118.21.224.224

Published: 2011

Journal Articles

Loss of the Cell Cycle Regulator p26 INCA1 Induces Exhaustion of Leukemic Stem Cells

Petra Tschanter, Nicole Baeumer, Lisa Lohmeyer, Frank Berkenfeld, Lara Tickenbrock, Sven Diederichs, Martin Stehling, Gabriele Köhler, Hubert Serve, MD, Wolfgang E. Berdel, Steffen Koschmieder, Carsten Müller-Tidow

Blood (2010) 116 (21): 96.

https://doi.org/10.1182/blood.V116.21.96.96

Published: 2010

Journal Articles

Phase I/II Study of BI 6727 (volasertib), An Intravenous Polo-Like Kinase-1 (Plk1) Inhibitor, In Patients with Acute Myeloid Leukemia (AML): Results of the Dose Finding for BI 6727 In Combination with Low-Dose Cytarabine

Gesine Bug, MD, PhD, Richard F. Schlenk, MD, PhD, Carsten Müller-Tidow, MD, PhD, Michael Lübbert, MD, PhD, Alwin Krämer, MD, PhD, Frank Fleischer, Tillmann Taube, MD, Oliver G. Ottmann, MD, PhD, Hartmut Doehner, MD, PhD

Blood (2010) 116 (21): 3316.

https://doi.org/10.1182/blood.V116.21.3316.3316

Published: 2010

Journal Articles

Sorafenib In Combination with Standard Induction and Consolidation Therapy In Elderly AML Patients: Results From a Randomized, Placebo-Controlled Phase II Trial

Blood (2010) 116 (21): 333.

https://doi.org/10.1182/blood.V116.21.333.333

Published: 2010

Journal Articles

Induction Therapy by Ara-C Plus Daunorubicin Versus Ara-C Plus Gemtuzumab Ozogamicin: Interim Analysis of a Randomized Phase II Trial of the SAL In Elderly Patients with Acute Myeloid Leukemia

Uta Brunnberg, Michael Mohr, Richard Noppeney, Heinz A. Duerk, Maria Cristina Sauerland, Carsten Müller-Tidow, Utz O Krug, Steffen Koschmieder, Torsten Kessler, Rolf M. Mesters, Christiane Schulz, Thomas Buchner, Gerhard Ehninger, Ulrich Dührsen, Hubert Serve, Wolfgang E. Berdel

Blood (2010) 116 (21): 335.

https://doi.org/10.1182/blood.V116.21.335.335

Published: 2010

Journal Articles

Genome Wide Screening Reveals Distinct Signaling Pathways of the ETS Transcription Factor ERG In Primary Acute Leukemia Blasts

Juliane Bock, PhD, Liliana H. Mochmann, Stefanie Göllner, PhD, Eckhard Thiel, Prof., Dr., Dr., h.c., Carsten Müller-Tidow, MD, Claudia Baldus, PhD

Blood (2010) 116 (21): 4184.

https://doi.org/10.1182/blood.V116.21.4184.4184

Published: 2010

Journal Articles

Addition of 5-Azacitidine to Standard Induction Therapy Is Feasible In Older Patients with Acute Myeloid Leukemia: The AML-AZA Trial of the SAL Study Group

Utz O Krug, MD, Anja Koschmieder, Joachim Gerss, PhD, Hubert Serve, MD, Björn Steffen, MD, Gesine Bug, MD, Markus Schaich, MD, Christian Brandts, MD, Christoph Röllig, MD, Gerhard Ehninger, MD, Ulrich Duehrsen, MD, Richard Noppeney, MD, Wolfgang E. Berdel, MD, Steffen Koschmieder, MD, Carsten Müller-Tidow, MD

Blood (2010) 116 (21): 2180.

https://doi.org/10.1182/blood.V116.21.2180.2180

Published: 2010

NARROW

Microrna-143 Blocks ERK5 Signaling During Granulocytic Differentiation of Hematopoietic Stem Cells and Is Downregulated in AML

Sorafenib Versus Placebo in Addition to Standard Therapy in Adult Patients ≥60 Years with Newly Diagnosed Acute Myeloid Leukemia: Results From the Randomized-Controlled Soraml Trial

Allogeneic Stem Cell Transplantation Versus Conventional Postremission Therapy for Acute Myeloid Leukemia in First Complete Remission: A Matched Pairs Analysis

DNA Methyltransferase 3B (DNMT3B) Protein Expression Predicts Survival in Patients with Acute Myeloid Leukemia (AML)

A Specific DNA Methylation Pattern Is Associated with Delayed Leukemogenesis and Altered Response to Chemotherapeutic Treatment in an Inducible DNMT3b Expressing Mouse Model

Phase I/II Study of Volasertib (BI 6727), An Intravenous Polo-Like Kinase (Plk) Inhibitor, in Patients with Acute Myeloid Leukemia (AML): Updated Results of the Dose Finding Phase I Part for Volasertib in Combination with Low-Dose Cytarabine (LD-Ara-C) and As Monotherapy in Relapsed/Refractory AML

Differential Activity of Pazopanib and Imatinib Against PDGFRA-Related MPN and AML

Identification of the PML-RARα Associated DNA Methylome Using Reduced Representation Bisulfite Sequencing in Primary Patient Samples

No Benefit of Combining Additional Compounds with Standard High Dose Cytarabine Consolidation: Results of the Prospective Randomized AML2003 Study

Loss of EZH2 and Aberrant DNA Methylation Account for PKC412 Drug Resistance in the FLT3-ITD Positive Acute Myeloid Leukemia (AML) Cell Line MV4-11,

A Distinct DNA Methylation Pattern Characterizes Childhood Acute Lymphoblastic Leukemia and Separates Patients Into Prognostic Groups,

DNMT3B Expression Delays Leukemogenesis,

Histone H3 Methylation Mediates All- Trans -Retinoic Acid Responsiveness in Acute Myeloid Leukemia

Loss of the Cell Cycle Regulator p26 INCA1 Induces Exhaustion of Leukemic Stem Cells

Phase I/II Study of BI 6727 (volasertib), An Intravenous Polo-Like Kinase-1 (Plk1) Inhibitor, In Patients with Acute Myeloid Leukemia (AML): Results of the Dose Finding for BI 6727 In Combination with Low-Dose Cytarabine

Sorafenib In Combination with Standard Induction and Consolidation Therapy In Elderly AML Patients: Results From a Randomized, Placebo-Controlled Phase II Trial

Induction Therapy by Ara-C Plus Daunorubicin Versus Ara-C Plus Gemtuzumab Ozogamicin: Interim Analysis of a Randomized Phase II Trial of the SAL In Elderly Patients with Acute Myeloid Leukemia

Genome Wide Screening Reveals Distinct Signaling Pathways of the ETS Transcription Factor ERG In Primary Acute Leukemia Blasts

Addition of 5-Azacitidine to Standard Induction Therapy Is Feasible In Older Patients with Acute Myeloid Leukemia: The AML-AZA Trial of the SAL Study Group

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only